World Journal of Surgery

, Volume 31, Issue 4, pp 695–704

Peripheral Arterial Occlusive Disease: Magnetic Resonance Imaging and the Role of Aggressive Medical Management

  • Alan B. Lumsden
  • Terry W. Rice
  • Changyi Chen
  • Wei Zhou
  • Peter H. Lin
  • Paul Bray
  • Joel Morrisett
  • Vijay Nambi
  • Christie Ballantyne
Article

Abstract

Atherosclerosis accounts for most peripheral arterial occlusive disease (PAD). Although many of the risk factors for atherosclerotic coronary artery disease (CAD) such as hyperlipidemia have been identified as risk factors for peripheral arterial disease, strong evidence is lacking that risk factor modification is effective in halting progression or improving outcomes. A better understanding is needed regarding the clinical and pathophysiologic responses to risk factor modification. This review describes current advances in the medical management for PAD including lipid modification antiplatelet therapy, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, exercise, and endovascular intervention. In addition, we discuss our active ELIMIT Trial (Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention). We test the hypothesis that an aggressive regimen of serum lipid modification will inhibit the progression of atherosclerosis in femoral arteries and reduce the incidence of restenosis of femoral arteries following endovascular stenting by decreasing thrombosis and inflammation. This study will provide a novel strategy for retarding or preventing progression of atherosclerosis and re-stenosis of peripheral arterial disease following arterial revascularization procedures. Importantly, our magnetic resonance imaging studies will provide quantitative data on the vascular lesions in PAD. These studies will advance our understanding of the molecular mechanisms of inflammation and thrombosis associated with aggressive lipid modification.

References

  1. 1.
    Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510–515PubMedGoogle Scholar
  2. 2.
    Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381–386PubMedCrossRefGoogle Scholar
  3. 3.
    Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602–609PubMedGoogle Scholar
  4. 4.
    Hiatt WR, Wolfel EE, Meier RH, et al. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 1994;90:1866–1874PubMedGoogle Scholar
  5. 5.
    McDermott MM, Mehta S, Ahn H, et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997;12:209–215PubMedGoogle Scholar
  6. 6.
    Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317–1324PubMedCrossRefGoogle Scholar
  7. 7.
    Rehring TF, Sandhoff BG, Stolcpart RS, et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005;41:816–822PubMedCrossRefGoogle Scholar
  8. 8.
    Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919–925PubMedGoogle Scholar
  9. 9.
    Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333–335PubMedCrossRefGoogle Scholar
  10. 10.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7–22CrossRefGoogle Scholar
  11. 11.
    Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577–1579PubMedGoogle Scholar
  12. 12.
    Dormandy J, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31:S1–S296PubMedCrossRefGoogle Scholar
  13. 13.
    Brown BG, Zhao XQ, Bardsley J, et al. Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States. J Intern Med 1997;241:283–294PubMedCrossRefGoogle Scholar
  14. 14.
    Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability. Am J Cardiol 1998;82(6A):5M–11MPubMedCrossRefGoogle Scholar
  15. 15.
    Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–1592PubMedCrossRefGoogle Scholar
  16. 16.
    LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340–2346PubMedCrossRefGoogle Scholar
  17. 17.
    Khan F, Litchfield SJ, Belch JJ. Cutaneous microvascular responses are improved after cholesterol-lowering in patients with peripheral arterial disease and hypercholesterolaemia. Adv Exp Med Biol 1997;428:49–54PubMedGoogle Scholar
  18. 18.
    Kirk G, McLaren M, Muir AH, et al. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc Med 1999;4:23–26PubMedGoogle Scholar
  19. 19.
    Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis (Cochrane review). In The Cochrane Library. Oxford, England: Update Software, 2001Google Scholar
  20. 20.
    Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991;83:438–447PubMedGoogle Scholar
  21. 21.
    Lewis B. Randomised controlled trial of the treatment of hyperlipidaemia on progression of atherosclerosis. Acta Med Scand Suppl 1985;701:53–57PubMedGoogle Scholar
  22. 22.
    Kroon AA, van Asten WN, Stalenhoef AF. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945–954PubMedGoogle Scholar
  23. 23.
    Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery 1996;120:672–679PubMedCrossRefGoogle Scholar
  24. 24.
    Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81:333–335PubMedCrossRefGoogle Scholar
  25. 25.
    Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of NCEP Adult Treatment Panel II guidelines: National Cholesterol Education Program. JAMA 1999;282:2051–2057PubMedCrossRefGoogle Scholar
  26. 26.
    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 2000;284:1263–1270PubMedCrossRefGoogle Scholar
  27. 27.
    Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005;96(5A):61F–68FPubMedCrossRefGoogle Scholar
  28. 28.
    Collins R, Baigent C, Sandercock P, et al. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists’ Collaboration. BMJ 1994;309:1215–1217PubMedGoogle Scholar
  29. 29.
    Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308:81–106Google Scholar
  30. 30.
    Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004;22(suppl 4):19–27PubMedCrossRefGoogle Scholar
  31. 31.
    Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001;103:2248–2253PubMedGoogle Scholar
  32. 32.
    Davi G, Averna M, Novo S, et al. Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. Atherosclerosis 1989;79:79–83PubMedCrossRefGoogle Scholar
  33. 33.
    Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247–251PubMedGoogle Scholar
  34. 34.
    Le Quan Sang KH, Levenson J, Megnien JL, et al. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol 1995;15:759–764PubMedGoogle Scholar
  35. 35.
    Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17–24PubMedCrossRefGoogle Scholar
  36. 36.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153PubMedCrossRefGoogle Scholar
  37. 37.
    Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589–1595PubMedCrossRefGoogle Scholar
  38. 38.
    Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001;87:1284–1286PubMedCrossRefGoogle Scholar
  39. 39.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421Google Scholar
  40. 40.
    Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105–2113PubMedCrossRefGoogle Scholar
  41. 41.
    Currie IC, Wilson YG, Scott J, et al. Homocysteine: an independent risk factor for the failure of vascular intervention. Br J Surg 1996;83:1238–1241PubMedCrossRefGoogle Scholar
  42. 42.
    Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149–1155PubMedCrossRefGoogle Scholar
  43. 43.
    Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230–235PubMedGoogle Scholar
  44. 44.
    Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523–530PubMedCrossRefGoogle Scholar
  45. 45.
    Liu Y, Shakur Y, Yoshitake M, et al. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001;19:369–386PubMedCrossRefGoogle Scholar
  46. 46.
    Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678–686PubMedGoogle Scholar
  47. 47.
    Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000;(2):CD000990Google Scholar
  48. 48.
    Ernst EE, Matrai A. Intermittent claudication, exercise, and blood rheology. Circulation 1987;76:1110–1114PubMedGoogle Scholar
  49. 49.
    Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis: report of a prospective randomized trial in a selected group of patients. J Vasc Surg 1989;9:1–9PubMedCrossRefGoogle Scholar
  50. 50.
    Wolf GL, Wilson SE, Cross AP, et al. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199. J Vasc Intervent Radiol 1993;4:639–648CrossRefGoogle Scholar
  51. 51.
    Holm J, Arfvidsson B, Jivegard L, et al. Chronic lower limb ischaemia: a prospective randomised controlled study comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty (PTA). Eur J Vasc Surg 1991;5:517–522PubMedCrossRefGoogle Scholar
  52. 52.
    Keller PJ, Drayer BP, Fram EK, et al. MR angiography with two-dimensional acquisition and three-dimensional display. Radiology 1989;173:527–532PubMedGoogle Scholar
  53. 53.
    Laub G, Kaiser W. MR angiography with gradient motion refocusing. J Comput Assist Tomog 1988;12:377–382CrossRefGoogle Scholar
  54. 54.
    Lenz GW, Haacke EM, Masaryk TJ, et al. In-plane vascular imaging: pulse sequence design and strategy. Radiology 1988;166:875–882PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2007

Authors and Affiliations

  • Alan B. Lumsden
    • 1
    • 2
    • 3
  • Terry W. Rice
    • 3
  • Changyi Chen
    • 2
  • Wei Zhou
    • 2
  • Peter H. Lin
    • 2
  • Paul Bray
    • 3
  • Joel Morrisett
    • 3
  • Vijay Nambi
    • 1
    • 3
  • Christie Ballantyne
    • 1
    • 3
  1. 1.Methodist DeBakey Heart CenterBaylor College of MedicineHoustonTexasUSA
  2. 2.Michael E. DeBakey Department of SurgeryHoustonTexasUSA
  3. 3.Department of MedicineBaylor College of MedicineHoustonTexasUSA

Personalised recommendations